Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Executive Summary
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
You may also be interested in...
Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
AbbVie To Take Flight From Galapagos As PELICAN Flounders?
Lacklustre top-line data from the PELICAN study raise concerns over AbbVie's commitment to Galapagos's cystic fibrosis franchise, and leaves rival Vertex even more securely in possession of the field.
Galapagos Glides Towards Triple Combo Studies In Cystic Fibrosis
Positive topline data from the ALBATROSS Phase II study suggest Galapagos's GLPG2222 is well tolerated and could bring additional therapeutic benefits to cystic fibrosis patients.